Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.

Key facts

Study ID

NCT00104130

Run by

Bristol-Myers Squibb

People needed

53

Starts

2004-12-01

Expected to finish

2005-02-01

Last updated by the study team

2008-09-17

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age.
• Metastatic disease.
• One previous treatment including docetaxel (Taxotere).
• At least 3 weeks since last surgery/radiation/chemotherapy
• ECOG Performance Status of 0, 1 or 2

You may not qualify if…

• Active brain metastases

Where it is running

• Kaiser Permanente Medical Center — Vallejo, California, United States
• Georgia Cancer Specialists — Tucker, Georgia, United States
• University of Maryland Medical System — Baltimore, Maryland, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• The Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Kaiser Permanente NW Oncology Clinic — Portland, Oregon, United States
• Oregon Health & Science University — Portland, Oregon, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.